阿贝西利联合内分泌辅助治疗高危早期乳腺癌:疗效更新与Ki-67分析
monarchE研究预设主要结局分析及额外随访显示,在高危早期乳腺癌中,阿贝西利联合内分泌治疗较单纯内分泌治疗显著改善无浸润性疾病生存(IDFS)和 distant relapse-free survival(DRFS),且获益不受Ki-67指数影响。
要点
- 阿贝西利联合内分泌辅助治疗显著降低高危早期乳腺癌IDFS事件风险(HR=0.71)。
- 额外随访27个月时IDFS和DRFS获益维持,3年绝对改善分别为5.4%和4.2%。
- Ki-67指数具有预后价值,但阿贝西利获益不受Ki-67指数影响。
核心结论
- 阿贝西利联合内分泌治疗显著改善激素受体阳性、HER2阴性、淋巴结阳性高危早期乳腺癌患者的IDFS,安全性可接受。
- Ki-67指数为预后因素,但阿贝西利获益与Ki-67指数无关。
- 阿贝西利的稳健治疗获益延伸至2年治疗期之后。
研究设计与样本
- 全球、III期、开放标签、随机(1:1)试验,共纳入5637例患者。
- 患者随机接受内分泌治疗≥5年±阿贝西利2年。
- 队列1:≥4枚阳性腋窝淋巴结,或1-3枚阳性淋巴结且组织学分级3级或肿瘤≥5 cm;队列2:1-3枚阳性淋巴结且中心检测Ki-67≥20%。
主要发现
- 主要结局分析中位随访19个月,阿贝西利+内分泌治疗降低29%的IDFS事件风险(HR=0.71,95%CI 0.58-0.87;名义P=0.0009)。
- 额外随访分析中位随访27个月,90%患者已停止治疗,IDFS获益维持(HR=0.70,95%CI 0.59-0.82;名义P<0.0001)。
- DRFS获益维持(HR=0.69,95%CI 0.57-0.83;名义P<0.0001)。
- 3年IDFS和DRFS绝对改善分别为5.4%和4.2%。
- Ki-67指数具有预后价值,但阿贝西利获益在各Ki-67亚组中一致。
关键数值与推荐
- 主要终点为意向治疗人群(队列1和2)的IDFS。
- 次要终点包括高Ki-67患者的IDFS、DRFS、总生存和安全性。
临床怎么用
- 对于激素受体阳性、HER2阴性、淋巴结阳性高危早期乳腺癌,可考虑阿贝西利联合内分泌辅助治疗。
- 治疗决策无需依据Ki-67指数筛选获益人群。
局限性
- 随访时间仍有限,主要分析中位随访19个月,额外分析27个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis. PATIENTS AND METHODS: This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for ≥5 years ± abemaciclib for 2 years. Cohort 1 enrolled patients with ≥4 positive axillary lymph nodes (ALNs), or 1-3 positive ALNs and either grade 3 disease or tumor ≥5 cm. Cohort 2 enrolled patients with 1-3 positive ALNs and centrally determined high Ki-67 index (≥20%). The primary endpoint was IDFS in the intent-to-treat population (cohorts 1 and 2). Secondary endpoints were IDFS in patients with high Ki-67, DRFS, overall survival, and safety. RESULTS: At the primary outcome analysis, with 19 months median follow-up time, abemaciclib + ET resulted in a 29% reduction in the risk of developing an IDFS event [hazard ratio (HR) = 0.71, 95% confidence interval (CI) 0.58-0.87; nominal P = 0.0009]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (HR = 0.70, 95% CI 0.59-0.82; nominal P < 0.0001) and DRFS (HR = 0.69, 95% CI 0.57-0.83; nominal P < 0.0001) benefit was maintained. The absolute improvements in 3-year IDFS and DRFS rates were 5.4% and 4.2%, respectively. Whereas Ki-67 index was prognostic, abemaciclib benefit was consistent regardless of Ki-67 index. Safety data were consistent with the known abemaciclib risk profile. CONCLUSION: Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67 index. Overall, the robust treatment benefit of abemaciclib extended beyond the 2-year treatment period.
引用
- Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021. PMID: 34656740. doi:10.1016/j.annonc.2021.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。